Primary refractory AML patients tended to express higher FIS1 transcripts than non-refractory patients (P = 0.059), for CN-AML, the tendency became statistically significant (P = 0.035), and was validated at protein level (P = 0.001, Fig. 3). Here, FIS1 is linked to acute myeloid leukemia.